Wnt7a is a novel inducer of β-catenin-independent tumor-suppressive cellular senescence in lung cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. DSCAM-AS1 Long Non-Coding RNA Exerts Oncogenic Functions in Endometrial Adenocarcinoma via Activation of a Tumor-Promoting Transcriptome Profile.Biomedicines · 2022
   Article
2. A Transcriptome Analysis: Various Reasons of Adverse Pregnancy Outcomes Caused by AcuteFrontiers in physiology · 2020
   Article
3. miR-127 suppresses gastric cancer cell migration and invasion via targeting Wnt7a.Oncology letters · 2019
   Article
4. High expression of WNT7A predicts poor prognosis and promote tumor metastasis in pancreatic ductal adenocarcinoma.Scientific reports · 2018
   Article
5. Loss of BRG1 induces CRC cell senescence by regulating p53/p21 pathway.Cell death & disease · 2017
   Article

Corrections and comments

• Erratum for
  Wnt7a is a novel inducer of β-catenin-independent tumor-suppressive cellular senescence in lung cancer.2015

Authors and funding

15 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.